CBD could help strengthen a light-based cancer treatment’s ability to destroy tumor cells, according to a new scientific paper examining the combination’s potential and the research still needed to establish its effectiveness.
The paper, published this month in the Journal of Photochemistry and Photobiology, was authored by Nkune Williams Nkune and Heidi Abrahamse of the University of Johannesburg’s Laser Research Centre in South Africa. The perspective article evaluates existing research rather than reporting a new clinical trial, with direct evidence for the combined treatment coming primarily from laboratory studies of cancer cells.
Photodynamic therapy uses a light-sensitive compound activated by specific wavelengths of light to generate reactive oxygen molecules that damage cancer cells. It can also trigger a form of cell death that alerts the immune system to a tumor. However, its effectiveness can be limited by poor light penetration, insufficient oxygen within tumors and conditions that suppress immune activity.
The authors describe several ways CBD might complement this treatment, including making cancer cells more vulnerable to oxidative damage and potentially changing the immune environment surrounding tumors.
Among the findings highlighted was a colorectal cancer cell experiment in which targeted photodynamic treatment left 31% of cells viable, compared with 44% following CBD alone. Combining the treatments reduced cell viability to 6%. These were laboratory results, not outcomes in patients.
Other experiments involving breast and liver cancer cells also reported stronger cancer-cell killing with CBD-containing combinations. In the breast cancer study, researchers examined CBD administered before, after or alongside photodynamic therapy, underscoring the potential importance of treatment timing.
The paper also explores nanoparticles that could deliver CBD and light-sensitive compounds together to tumors. Such systems could improve drug stability and delivery, although their safety and effectiveness require further investigation.
Despite the encouraging findings, the authors identify substantial gaps. The combination studies reviewed did not directly establish that increased cancer-cell death produced a stronger antitumor immune response. They also lacked the analyses needed to determine whether the treatments were truly synergistic, meaning their combined effect exceeded the sum of their individual effects.
CBD’s effects on immunity can also vary with dose and context, potentially suppressing immune activity under some conditions. The authors say dosing, treatment sequencing, interactions with other drugs and effects on healthy tissue need careful evaluation.
“In conclusion, the combination of PDT and CBD rational holds great promise as a synergistic approach to overcome the inherent limitations of each agent while augmenting antitumour immunity”, states the study’s researchers. They finish their conclusion by stating:
PDT exerts localised ROS-mediated cytotoxicity and ICD; however, its efficacy is hampered by poor light penetration, tumour hypoxia and an immunosuppressive TME. CBD complements PDT by sensitising cancer cells to oxidative stress, modulating dendritic cell maturation, reducing immunosuppressive cytokines, and promoting T-cell infiltration, thereby transforming the TME from a suppressive to a stimulatory state.Preclinical evidence, though still in its infancy, showed enhanced cancer cell death, intratumoral CD4+/CD8+ T-cell recruitment, and systemic immune effects when PDT and CBD are combined. Nanotechnology-based co-delivery systems also hold great promise for enhancing bioavailability, tumour targeting and controlled release. To successfully translate PDT-CBD combination therapy into clinical practice, several key steps are essential: understanding the molecular mechanisms underlying CBD and PDT synergy through mechanistic studies; optimising treatment protocols (including administration sequence, dosing and light parameters); validating the approach in immunocompromised, nude and humanised models; systematically evaluating the combination of CBD/PDT with immune checkpoint inhibitors; developing scalable nanocarrier formulations; conducting Phase I trials to assess safety, pharmacokinetics and drug interactions; and identifying biomarkers for patient stratification. Addressing these challenges could enable CBD/PDT to evolve from a localized ablation method into a systemic immunotherapeutic modality, offering durable anti-tumor responses, preventing recurrence and metastasis, and significantly enhancing future cancer immunotherapy strategies.










